Skip to content
sellWeak cluster of 210b5-1 plan

James Mulay sold $500k of CGON

director at CG Oncology, Inc.. 12,755 shares at an average of $39.19, traded Sep 29, 2025, filed Sep 30, 2025.

Warning score
26
Value
$500k
12,755 shares
Holdings after
0
-100% from before
From 52-week low
+151%
low $15.59, close $39.08
From 52-week high
-2%
high $39.94, as of Sep 29, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $500k at market
    +18
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

CGONOct 9, 2026 · close 63.82
Since filing Sep 30, 2025: +58.4%SPY +18.1% · excess +40.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001193125-25-225133, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Sep 29, 2025MOption exercise
Common Stock10b5-1
+12,755$1.82$23k12,755Sep 30, 2025
Sep 29, 2025SOpen-market sale
Common Stock10b5-1
-12,755$39.19$500k0Sep 30, 2025
Sep 29, 2025MOption exercise
Director Stock Option (right to buy)derivative10b5-1
-12,755$0.00$00Sep 30, 2025

Related signals

Other insiders at CG Oncology, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
8Weak
CGONsell10b5-1
CG Oncology, Inc.
Leonard E Post
director
$73k
1,000 shares
-100%
10Weak
CGONsell10b5-1
CG Oncology, Inc.
James Mulay
director
$125k
1,964 shares
-300%
19Weak
CGONsell10b5-1
CG Oncology, Inc.
James Mulay
director
$585k
11,145 shares
-1704%
6Weak
CGONsell10b5-1
CG Oncology, Inc.
Leonard E Post
director
$41k
1,000 shares
-100%
14Weak
CGONsell 210b5-1
CG Oncology, Inc.
Leonard E Post
director
$43k
1,000 shares
-100%
21Weak
CGONsell 210b5-1
CG Oncology, Inc.
James Mulay
director
$260k
5,903 shares
-100%
20Weak
CGONsell 210b5-1
CG Oncology, Inc.
Leonard E Post
director
$200k
5,000 shares
-100%
31Weak
CGONsell 210b5-1
CG Oncology, Inc.
James Mulay
director
$885k
22,686 shares
-119%
21Weak
CGONsell 310b5-1
CG Oncology, Inc.
Leonard E Post
director
$35k
1,000 shares
-100%
37Weak
CGONbuy10b5-1
CG Oncology, Inc.
Brian Guan-Chyun Liu
director
$50M
1,515,151 shares
-

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

James Mulay sold $500k of CGON | InsiderTell